Bristol-Myers Squibb Co (BMY)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$54.66
Buy
$54.82
$-0.57 (-1.03%)
Prices updated at 08 Nov 2024, 00:59 EST
| Prices minimum 15 mins delay
Prices in USD
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2022 | 2023 |
---|---|---|
46,159m | 45,006m | |
36,022m | 34,313m | |
9,104m | 8,195m | |
19.72 | 18.21 | |
6,327m | 8,025m | |
19,221m | 19,366m | |
Sales, General and administrative | 7,814m | 7,772m |
Interest expenses | 1,232m | 1,166m |
Provision for income taxes | 1,368m | 400m |
Operating expenses | 26,918m | 26,118m |
Income before taxes | 7,713m | 8,440m |
Net income available to common shareholders | 6,327m | 8,025m |
2.97 | 3.88 | |
Net interest income | -1,232m | -1,166m |
Advertising and promotion | - | - |
Net investment income, net | - | - |
Realised capital gains (losses), net | - | - |
Total benefits, claims and expenses | - | - |
Earnings per share (diluted) | 2.95 | 3.86 |
Free cash flow per share | 5.862 | 5.5655 |
Book value/share | 15.7451 | 14.3483 |
Debt equity ratio | 1.169215 | 1.297418 |
Balance sheet
Year | 2022 | 2023 |
---|---|---|
Current assets | 27,273m | 31,770m |
Current liabilities | 21,890m | 22,262m |
Total capital | 66,117m | 66,083m |
Total debt | 40,717m | 41,464m |
Total equity | 31,061m | 29,430m |
Total non current liabilities | - | - |
Loans | 35,056m | 36,653m |
Total assets | 96,820m | 95,159m |
Total liabilities | - | - |
Cash and cash equivalents | 9,123m | 11,464m |
Common stock | 2,075m | 2,021m |
Cash flow
Year | 2022 | 2023 |
---|---|---|
Cash at beginning of period | 14,316m | 9,325m |
Cash dividends paid | -4,634m | -4,744m |
11,948m | 12,651m | |
Investments (gains) losses | -1,062m | -2,295m |
9,325m | 11,519m | |
Net income | - | - |
13,066m | 13,860m | |
-1,118m | -1,209m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.